

Watts: 1-888-868-8367 (TOTTENS) Fax: 1-888-232-2205

New Submissions: casualty@tottengroup.com Website: www.tottengroup.com

PHARMACEUTICAL CONTAMINATION INSURANCE APPLICATION

Underwriters will rely upon each and every response given in this Proposal Form and any Supplementary Proposal Form in deciding whether or not to insure this risk and if so at what premium, terms and conditions. Underwriters regard every response to be material to their decisions. Failing to answer or answering any question below incorrectly could invalidate any policy of insurance written by Underwriters for this risk.

We have a professional duty of confidentiality and are committed to holding personal information in strict confidence. The information provided to us will only be disclosed where required by law to do so or required to do so in conducting negotiations with third parties, such as insurance companies, on your behalf.

We will further safeguard the security of such information in a manner appropriate to sensitivity of that information.

1. 2.	(and all subsidiaries)					
			Website			
3.	Main Contact Name			ne		
4.	Describe business of Applicant					
5. 6.		Product category				
	Product	% of Total Sales	Target Market	% Share of Market		
7. 8.	Please indicate estimated annual sales Total number of plants/facilities Please provide the following					
	Sales by country United Kingdom European Union	20	20	20		
	USA/Canada Rest of World					
9.	Is any sales are registered in the European Community and Rest of World, please indicate in which states European Union					
	Rest of World					

1 of 6



10.	List company's products sold as part of or under another company's label or brand name					
	What percentage of your products are an ingredient/raw material of other products?		%			
1.	Please indicate any new products that have commenced production or have entered the public stream of commerc 12 months	e within th	e last			
	What percentage of your products is manufactured by an outside vendor?		9			
3.	Has the applicant agreed to indemnify, hold harmless or contractually restrict in any way, liability in respect of suppliers of products, goods or services (eg suppliers of raw materials or packaging, or contract packers)?	☐ Yes	□ No			
	If yes, please provide details					
4.	Total number of company employees					
	List below any strikes, riots, work stoppages and/or plant closings in the last three (3) years					
5.	Has the company ever been a direct target of political, racial, environmental, or other extremist or special interest					
	groups?	☐ Yes	□ No			
	If yes, please provide details					
	Does the company use or pay for animal testing of products?	☐ Yes	□ No			
	If yes, please provide details					
	Does the company import/export with volatile countries or undertake other activities which might make it a target of extremist or special interest groups?	☐ Yes	□ N			
	If yes, please provide details					



16. Please provide the following information for the top 3 selling products

	Product 1	Product 2	Product 3
Product Name			
Product Type			
Is it a finished product			
How long have you been manufacturing the product? (for generics only)			
Shelf Life (weeks, months or years)			
Packaging Type (please specify)			
Annual Turnover (£/\$)			
Daily Production (£/\$)			
Daily Production (Units)			
Plant Locations where product is produced			
Number of Production Lines at each location			
Country(ies) where sold			
Largest Batch Size by Value (£/\$)			



QUALITY AND SAFETY

17.	Do you have a documented and active Quality and Safety Program? (please attach copy)	☐ Yes	□No			
18.	Does the program incorporate and comply with FDA Current Good Manufacturing Practice Regulations (cGMPs) and incorporate Quality Risk Management, such as FDA Guidance: Guidance for Industry, Q9 Quality Risk Assessment) for all products?					
	Date cGMPs last reviewed and updated					
	Does the plan incorporate a Quality Risk Management Process?	☐ Yes	☐ No			
	When was the date of the last Good Manufacturing Practices (cGMPs) audit?					
	(Please attach copy of the most recent audit report)					
	Which allergens are used?					
	Is there an Allergen Management Program in place to prevent cross contamination?					
19.	Is there a Quality and Safety Department?	☐ Yes	☐ No			
	Who is responsible for overseeing and implementing cGMPs?					
	Is this person dedicated full time to such work?	☐ Yes	☐ No			
	If "no", please indicate other responsibilities held by this person					
20.	In respect of the manufacture and distribution of pharmaceutical products, are you audited to confirm compliance verguirements of:	vith the reg	ulatory			
	☐ MHRA ☐ FDA ☐ EMEA ☐ Other					
	How often are audits performed?					
	Are audits performed at all your sites?	☐ Yes	☐ No			
	Give details of any major recommendations made that have not been implemented					
21.	Do you require your suppliers to abide by quality and safety standards that include cGMPs and Quality Risk Management?	☐ Yes	□No			
	If no, what steps are taken?					
	What steps are taken to assess the quality and safety standards adhered to by your suppliers? (e.g., supplier audits, application, questionnaire, references, health inspection reports, etc.)					
	Who (what position(s)) decides whether a supplier is approved?					
	Do you have a formal supplier qualification process?	☐ Yes	☐ No			



22.	Relating to your Product Testing	(please select the applicable b	poxes)				
	Product Test Type	Raw Materials	In-Line	End of Line			
	Microbiological						
	X-Ray						
	Metal Detectors						
	Physical						
	Chemical						
23.	Do you have an in-house testing	laboratory?		☐ Yes	☐ No		
	If yes, what types of tests are conducted by the in-house laboratory?						
	If no, do you retain an outside testing laboratory?				□No		
	If yes, Name of laboratory						
	Location of laboratory						
	Is it open 24 hours?			☐ Yes	☐ No		
	Are they accredited to ISO EN 1	7025		☐ Yes	☐ No		
	Is there a hold period before shipping?				☐ No		
	Is there a "positive release" proc	☐ Yes	☐ No				
	Is there an incoming quarantine	☐ Yes	☐ No				
	Are certificates of product conformance or certificates of analysis (COAs) from the suppliers received?				☐ No		
24.	Are all your product labels inspe-	cted?		☐ Yes	☐ No		
	If yes, when and by whom?						
25.	Do you collect and monitor custo	omer complaints		☐ Yes	□No		
	If yes, how? ☐ Internet Site ☐	Free phone number	etronic (i.e. database) 🗌 Other				
REC	CALL PREPAREDNESS						
26.	Is there a written and active reca	-		Yes	_		
	Is there a formal recall team in place?				☐ No		
	Has the recall plan been tested within the past 12 months? Have all members of the recall team been trained within the past 12 months?				☐ No		
	Please provide a copy of the re	·			_		
27.		-		☐ Yes	□ No		
	Is there a formal MPT/defense to	•		_ □ Yes	☐ No		
	Have all members of the MPT/de	efense team been formally train	ned within the past 12 months?	☐ Yes	☐ No		
	Please provide a copy of the p	lan					
28.	Have the company's products or governmental agency or departn		the subject of comment or complaint		□No		
	If yes, Which agency or departm						
	Date and nature of comment or complaint						
	Outcome of such comment or complaint						
	Date resolved						



29.	Claims history of the company			
	Products recalled due to an accidental contamina	ation and/or malicious tampering in the last ten (10) years		
	Division and product			
	Reason for recall			
	Date of recall			
	Recall method utilized			
	Cost of recall			
	Were any contracts lost/discontinued as a result?	(continue on separate sheet if necessary)	☐ Yes	□No
30.	Does the company know of any actual, threatened or suspected product tampering involving any of the company's products during the last twelve (12) months?			☐ No
	If yes, please give details			
31.		ny other person known to the Insured have knowledge or reasonably give rise to a claim under the proposed policy?	☐ Yes	□No
	Limits of Liability Requested			
	Accidental Contamination	Malicious Tampering		
	Self-Insurance Retention Requested			
	Accidental Contamination	Malicious Tampering		
Plea	ase enclose with this proposal form			
□ F	Recall Plan 🔲 Crisis Management Plan 🔲 cGM	P Audit Report	ogram Polic	су
Duty	y of Disclosure			
you whe	r business) and which might influence an insurer's ju ether any information is material, you should disclo	on that is known to you (or which ought to be known to you in the adgment in determining whether or not to accept your risk. If you are ose it. Failure to disclose all material information may entitle instant of all claims and to require repayment of all claims previous	in any dou urers to av	bt as to
I/We part mat I/We	ticulars which may affect the assessment of the risk terial change to the information already provided when the contract of the provided when the contract of	belief the answers given are true and complete in every respect at have been disclosed. Furthermore, I/We undertake to inform you hether before or after a contract of insurance is finalised. Firm does not bind me to a contract of insurance, but agree that sho deemed incorporated into such contract of insurance.	ı if there is	any
	Applicant Signature	Date		
	Printed Name	Position in Organizati	ion	
		and we are free to choose the law applicable to this contract, unless spec		∍d to
	Complete Nat	me and Address of Insurance Brokerage		
Bro	oker Email Address:			